Three top-quality global stocks that will stand the test of time
Professional investor Tom Wildgoose of the Nomura Global High Conviction Fund picks three stocks from overseas markets that should stand UK investors in good stead.
When it comes to investing, sticking with what we know makes sense, especially in uncertain times (which seem to be all the time). As I am British, UK stocks seem familiar to me. The largest is AstraZeneca – everyone knows AstraZeneca. The second-biggest is HSBC, followed by GlaxoSmithKline. These are companies we can feel comfortable with, you might think; no need to look further.
In its 2018 European Asset Allocation Survey of institutional investors, Mercer, the investment consultant, found that UK investors keep 28% of their equity allocation in British markets (compared with the UK’s 4% weighting in global equity indices) and it’s the same for Europeans generally, with a 38% allocation to home equity markets.
A global footprint
AstraZeneca’s US revenue is 80% higher than its European revenue. Almost 50% of HSBC’s revenue comes from Asia, and it’s a similar story at GlaxoSmithKline. So we are more familiar with international markets than we thought.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The problem is that the FTSE 100 is skewed away from highly profitable, or “quality” companies. The largest ten companies in the UK market have an average expected “post-Covid-19” return on equity (ROE, a key gauge of profitability) of 23%. The largest ten in the MSCI World Index, a broader global index, have an average expected post-Covid-19 ROE of 38%.
Over the last decade the MSCI World Quality Index has outperformed MSCI World by almost 90% and the FTSE 100 by almost 195%. For the ten years before that, MSCI World Quality beat MSCI World by 14%, but in the decade before that the gap was 309%. So buying “quality” works, but buying British doesn’t seem to be a “quality” buy.
The companies on the UK market are not generally of the quality that can generate good long-term investment returns. Unilever is listed in London and is a very good company, but how about looking at a company like Mastercard, which we are all familiar with?
“Quality” does not simply mean “growth”. Many of the top-performing funds over the last few years have focused on rapidly-growing companies but the inverse correlation of “growth” stocks’ returns with bond yields is clear. Should inflation come back, bond yields are likely to rise, reflecting falling bond prices. “Quality” has stood the test of time whereas “growth” is likely to suffer if bond yields rise (higher interest rates temper growth).
Three top tips
Here are three global stocks that we think are “quality”, but not necessarily “growth”. One is Inditex (Madrid: ITX). This is the Spanish company behind Zara. Naturally the pandemic has affected sales, but it has a strong balance sheet and a growing online business.
Then there is Novo Nordisk (Copenhagen: NOVO-B), a Danish diabetes-treatment maker with a terrific record on environmental, social and governance issues and a head-start on the competition in oral-diabetes treatments. Finally, Pepsico (Nasdaq: PEP) is a high-quality soft-drinks, snacks and foods maker whose brands include Quaker Oats and Pepsi Cola. Its ROE and history of dividend payments are both attractive.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
HMRC confirms crypto ETN ISA rules
With crypto ETNs now technically available for UK retail investors, HMRC has confirmed they can be held in an ISA – but there’s a complication
-
Pensioners targeted in fine wine scams – the tactics to watch for
Wine has emerged as the latest lure in investment fraud, with pensioners being specifically targeted by scammers
-
Pierre-Édouard Stérin wants to make France great again
Conservative billionaire Pierre-Édouard Stérin is seeking to lead a political and spiritual renaissance across the Channel. The planning looks meticulous
-
Global investors have overlooked the top innovators in emerging markets
Opinion Carlos Hardenberg, portfolio manager, Mobius Investment Trust, highlights three emerging market stocks where he’d put his money
-
Pinewood Technologies: a drive for growth
Pinewood Technologies’ platform is one of the best in the business. Investors should buy in
-
'EV maker Faraday Future will crash'
Faraday Future Intelligent Electric is failing dismally to live up to its name, says Matthew Partridge
-
Investors should cheer the coming nuclear summer
The US and UK have agreed a groundbreaking deal on nuclear power, and the sector is seeing a surge in interest from around the world. Here's how you can profit
-
8 of the best houses for sale with follies
The best houses for sale with follies in the grounds – from a five-storey Victorian Gothic tower in Tonbridge, Kent, to a former mill in Oxfordshire with gardens that include a folly on an island in a lake
-
A tale of two Reits – why performance matters for valuation
AEW UK and Regional are two Reits that are valued very differently, despite a shared focus on properties outside London
-
Healthcare stocks look cheap, but tread carefully
Shares in healthcare companies could get a shot in the arm if uncertainty over policy in the US wanes, but are they worth the risk?